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Abstract: Medullary thyroid cancer (MTC) represents an aggressive form of thyroid malignancy. Some may occur spontaneously or 
can be associated with Multiple Endocrine Neoplasia syndromes, or Familial Medullary Thyroid Cancer syndrome. In these patients, the 
protooncogene RET (rearranged during transfection) is mutated. In patients who have unresectable or metastatic disease, the long term 
prognosis is poor. New treatments for this disease have focused on the use of targeted agents that inhibit the receptor tyrosine kinase of 
RET. One of these treatments, Vandetanib (Caprelsa, Astra Zeneca), recently has received approval from the Food and Drug Adminis-
tration for the treatment of patients with progressive locally advanced and/or metastatic disease. This review highlights the studies that 
led to the drug’s approval, and discusses on the potential financial costs of treatment and side effects of this therapy. The main clinical 
studies evaluating Vandetanib for the treatment of other solid tumors will also be reviewed.
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Introduction
Medullary  thyroid  cancer  (MTC)  account  for 
5% to 8% of thyroid carcinomas and arise from the 
  calcitonin  producing  parafollicular  cells  (C  cells).1 
MTC is often asymptomatic when localized and as 
a result, 50% of patients have unresectable disease at 
the time of diagnosis. The hypercalcitonism typically 
seen  with  a  larger  burden  of  metastatic  or  locally 
advanced disease can result in systemic symptoms 
such as diarrhea, bone pain, or flushing. The prognosis 
for these patients remains poor, with only 40% of the 
patients alive after 10 years. Conversely, when the 
tumor is confined to the thyroid gland, the 10 year 
survival rate is approximately 95%.2–4 Conventional 
cytotoxic chemotherapy regimens as well as   radiation 
therapy have been used in the treatment of unresect-
able MTC with limited success; unfortunately, they 
do  not  prolong  survival.5–7  The  gap  in  prognosis 
between localized and metastatic disease emphasizes 
the importance of early detection and the necessity of 
finding new therapeutic agents for advanced MTC.
Over the past decades, significant progress has been 
made in the understanding of MTC’s   pathogenesis. 
Indeed, it has been shown that the proto-oncogene 
RET (Rearranged During Transfection), located on 
chromosome 10, is responsible for the development of 
both familial medullary thyroid cancer (FMTC) and 
sporadic MTC. RET mutations are observed in both 
sporadic MTC and FMTC. MTC can also be associ-
ated with other endocrine tumors, such as pheocro-
mocytomas and primary hyperparathyroidism. These 
disorders, called the Multiple Endocrine Neoplasia 
Syndromes  (MEN  2A  and  MEN  2B),  explain  the 
remaining 65% of hereditary MTC, with respectively, 
55% and 10% of the cases.8
The understanding of MTC’s biology uncovered a 
possible role for targeted therapies in this malignancy. 
The recently approved small molecule   Vandetanib, 
which  targets  the  RET,  Epidermal  growth  factor 
(EGF) and Vascular endothelial growth factor (VEGF) 
receptors, is a new therapeutic option for advanced 
MTC where classic chemotherapy regimens and radi-
ation therapy are ineffective. This review will discuss 
recurrent molecular alterations observed in MTC and 
the means to target them. We will discuss the clini-
cal studies that led to Vandetanib approval for MTC. 
Vandetanib’s effectiveness, side effects, and cost will 
be  analyzed.  The  main  clinical  studies  evaluating 
Vandetanib for the treatment other solid tumors will 
also be reviewed.
The ReT, VeGF-R and eGF-R 
pathways in MTc
The ReT (rearranged during 
transfection) proto-oncogene
The RET proto-oncogene codes for a tyrosine-kinase 
receptor (TKR). These glycoproteins, including RET, 
receive  extra-cellular  signals  and  form  homo-  or 
hetero-dimers in response to binding of extracellular 
ligands. Their activation can lead to various cellular 
processes, such as differentiation, proliferation, apop-
tosis, or cell motility, depending on the ligand and 
receptor involved.9 The RET proto-oncogene encodes 
a receptor tyrosine kinase that is activated by the glial 
cell line-derived neurotrophic factor (GDNF) family. 
GDNF  forms  a  complex  with  glycosylphosphati-
dylinositol (GPI)-anchored co-receptor, which links 
two RET proteins that initiate autophosphorylation of 
specific tyrosine residues within the tyrosine kinase 
domain of each RET molecule.10 Different pathways, 
including RAS-MAPK and PI3K-AKT, are activated 
downstream  from  the  RET  receptor  and  contrib-
ute to cell survival and proliferation (Fig. 1). RET 
  proto-oncogene was first described in papillary thy-
roid cancer (PTC) where translocations involving the 
RET gene give rise to an aberrant fusion oncoprotein 
(RET/PTC), leading to constitutive activation of the 
RET  receptor.11  Different  point  mutations  increas-
ing  RET  receptor TKR  activity  subsequently  have 
been described. These gain of function mutations are 
observed in MTC, FMTC, MEN 2A, MEN 2B and a 
subset of sporadic pheocromocytomas.12,13   Conversely, 
RET loss of function mutations are associated with 
Hirschprung’s disease.14
The veGF-R pathway
Tumors require constant nutrient and oxygen   supply. 
Consequently, they develop a neo-vasculature through 
a process called angiogenesis, particularly when they 
are growing rapidly. In contrast with physiologic situ-
ations such as wound repair, this process is deregu-
lated in human malignancies in the form of constant 
activation. The most important angiogenesis stimu-
lating pathway is VEGF signaling, where VEGF-A 
binds the VEGF tyrosine kinase receptors 1, 2 or 3 vandetanib for medullary thyroid cancer
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(VEGFR-1-3) leading to proliferation, survival, and 
migration of endothelial cells.15 A recent study showed 
that VEGF-A, VEGFR-1 and VEGFR-2 are overex-
pressed in more than 90% of MTC. No correlation 
between VEGF-A expression and extent of disease 
was found. The only prognostic factor related to vas-
culature identified by the investigators was micro-
vessel density (MVD). Indeed, MVD was associated 
with poor prognosis, and all the patients with high 
MVD  died.16 Another  study  showed  that  in  MTC, 
the expression of VEGFR-2 is significantly higher in 
metastases compared to primary tumors.17
The eGFR (epidermal Growth  
Factor Receptor) pathway
EGFR is a tyrosine kinase cell surface receptor acti-
vated by epidermal growth factor (EGF) and transform-
ing growth factor alpha (TGFα). Upon stimulation by 
these ligands, the receptor forms a homodimer or a 
heterodimer with another member of the EGFR fam-
ily, allowing auto-phosphorylation of several tyrosine 
residues of the receptor which in turns leads to activa-
tion of the downstream MAPK, AKT and JAK path-
ways involved in cell proliferation, migration, and 
adhesion  (Fig.  1).18  Mutations  and  overexpression 
of  EGFR  are  observed  in  numerous  malignancies, 
including lung cancer,19 glioblastoma multiforme,20 
anaplastic thyroid cancer,21 papillary thyroid cancer22 
and MTC. Indeed, a recent study showed that 13% 
of MTC overexpress EGFR. Strikingly, 35% of the 
metastases tested displayed overexpression of EGFR, 
suggesting that this signaling pathway might play an 
important role in advanced disease.17
The small molecule vandetanib targets 
the ReT, eGF and veGF receptors
RET  mutations  are  believed  to  be  the  primary 
oncogenic  event  in  a  majority  of  MTC.  Sustained 
angiogenesis  is  presumed  to  contribute  to  the 
pathogenesis of MTC. In addition, EGFR is specifi-
cally  overexpressed  in  advanced  MTC.  Therefore, 
it seems reasonable to postulate that blocking these 
pathways  might  reverse  cell  growth  and  prolifera-
tion.  The  small  molecule    Vandetanib  was  shown 
to  block  MTC  cell  lines  proliferation  in  vitro  by 
blocking  RET  activity.23  Interestingly,  upon  RET 
inhibition,  the  proliferative  capacity  of  MTC  cell 
lines can be rescued, in part, by EGFR   stimulation. 
This emphasizes the necessity to block these pathways 
simultaneously.24  Vandetanib  competes  with  ATP 
  binding in the catalytic domain of several tyrosine 
kinases. In vitro assays showed that   Vandetanib is a 
potent inhibitor of VEGFR-2, VEGFR-3, EGFR, and 
RET kinases. This activity profile made it an optimal 
choice for evaluation in clinical trials.25
Pharmacokinetics and 
pharmacodynamics of vandetanib
The  two  first  phase  I  studies  showed  that  absorp-
tion  and  elimination  of  Vandetanib  after  a  single 
oral dose of 300 mg was slow: the time to maximum 
concentration  ranged  from  4  to  7.5  hours  and  the 
Figure 1. A schematic drawing of the interaction of ReT, eGFR and veGFR with growth factor pathways.
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terminal   half-life was approximately 90–120 hours. 
  Steady-state  plasma  concentrations  were  obtained 
after  1  month  of  daily  dosing.26,27  Other  phase  I 
studies  were  subsequently  conducted  with  healthy 
volunteers  to  further  characterize  pharmacokinetic 
parameters such as metabolism and excretion. One 
study found a longer terminal half-life of approxi-
mately 10 days, compared with the 4 or 5 days of 
the previous studies. The absorption of Vandetanib 
was only slightly reduced by concomitant ingestion 
of food. Unchanged Vandetanib and three metabolites 
(N-desmethylvandetanib,  vandetanib  N-oxyde  and 
glucuronide conjugate of vandetanib) were detected in 
plasma, urine and feces.28 In vitro studies showed that 
Vandetanib is converted into N-  desmethylvandetanib 
by the CYP P450 3A4 and it has subsequently been 
demonstrated  that  Vandetanib  exposure  can  be 
modified  when  administrated  in  combination  with 
CYP 3A4 inducers or inhibitors.29 Approximately one 
half (44%) and one fourth (25%) of the Vandetanib 
dose  was  recovered  over  21  days,  in  respectively, 
feces and urine, suggesting that these two routes might 
play  an  important  role  in  Vandetanib    elimination. 
  Vandetanib  exposure  is  increased  in  patients  with 
renal impairment whereas exposure seems unchanged 
in patients with hepatic impairment.30 Recombinant 
enzyme assays showed that Vandetanib is a potent 
inhibitor of VEGFR-2 (IC(50) = 40 nM), VEGFR-3 
(IC(50) = 110 nM), EGFR (IC(50) = 500 nM) and 
RET (IC(50) = 130 nM) and that the selectivity for 
these receptors was excellent.31
Phase I studies
In a first phase I study, 77 patients were enrolled in 
the  USA  and Australia. The  patients  all  had  solid 
tumors refractory to treatment, or had a cancer with 
no  established  treatment.  They  received  a  single 
dose of the drug, ranging from 50 mg to 600 mg, fol-
lowed by 7 days of observation. After the observation 
period, they received the same dose once a day for 
28 days until progression or dose-limiting toxicity. 
The most common drug related adverse events were 
diarrhea,  rash,  nausea,  hypertension,  and  fatigue. 
Seven  patients  experienced  an  asymptomatic  QTc 
interval prolongation. At 500 and 600 mg, three and 
seven out of eight patients respectively, experienced 
dose-limiting toxicities. Thus, 300 mg was the high-
est dose used during the cohort expansion phase of 
the study.26 A second phase I study was conducted 
in Japan with 18 patients. The dose-limiting toxici-
ties were hypertension, diarrhea, headache, and toxic 
skin eruption. Again, 300 mg was identified to be the 
recommended dose. This study showed an objective 
response in some patients with non-small cell lung 
carcinoma.27 A phase I study was recently conducted 
in China and enrolled 36 patients with solid malignant 
tumors, mostly lung cancers. The patients received 
three different doses of Vandetanib (100 mg every 
other day, 100 mg daily or 300 mg daily) until disease 
progression or discontinuation of the study. Again, 
the most common drug-related side effects were rash 
and   diarrhea, with respectively 42% and 39% of the 
patients. Three patients with MTC were included in 
this study. Interestingly, one of these patients, treated 
with 300 mg daily, was the only patient of the whole 
study  who  had  an  objective  partial  response.  The 
investigators  compared  the  pharmacokinetic  data 
with the previous phase I studies and concluded that 
there was no marked difference in pharmacokinetics 
among Chinese, Japanese and Western patients.32
Phase II studies: vandetanib in MTC
A  first  multicenter  phase  II  study  was  initiated  in 
November 2004 and enrolled patients with unresect-
able locally advanced or metastatic hereditary MTC 
until August 2006. Thirty patients received 300 mg 
Vandetanib  a  day  and  were  assessed  for  objective 
tumor response following the Response Evaluation 
Criteria in Solid Tumors (RECIST). Secondary end 
points  included  progression-free  survival  (PFS), 
duration of response, disease control, safety and tol-
erability as well as changes in serum levels of MTC 
  biomarkers. Determination of response was assessed 
by computed tomography (CT) and magnetic reso-
nance  imaging  (MRI)  obtained  initially  and  after   
12 week-intervals during treatment. Durable stable dis-
ease (.24 weeks) was observed in 16 out of 30 patients 
(53%). Partial responses were reported in six patients 
(20%). Thus, 22 patients (73%) had disease control 
on Vandetanib. Notably, 25 patients (83%) experi-
enced some reduction in tumor size during   treatment. 
The median duration of response (from first response 
to  progression  or  death)  was  10.2  months  (range, 
1.9–16.9).  The  median  progression-free  survival 
was  27.9  months.  Six  patients  had  stable  disease 
for less than 24 weeks, one patient had progressive vandetanib for medullary thyroid cancer
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  disease, and one patient was not evaluable because of 
impaired renal function. Serum tumor markers also 
were analyzed; the criteria for partial response was a 
decrease from baseline calcitonin and carcinoembry-
onic antigen (CEA) level. Decrease of baseline cal-
citonin and CEA was observed in 24 patients (80%) 
and 16 patients (53%), respectively. All patients with 
a partial response (n = 6) on imaging studies had a 
decrease (range, 73% to 99%) in serum calcitonin 
  levels, and 4 partial responders had a marked decrease 
in CEA serum levels (range, 82% to 91%). At the time 
of data cutoff (February 22, 2008), 17 patients were 
still on treatment. Regarding safety and tolerability, 
7 patients (23%) discontinued the treatment. Five out 
of 7 discontinuations were attributed to Vandetanib-
related adverse events, including QTc prolongation, 
rash, nausea, and hemorrhagic diarrhea. In the whole 
cohort,  the  most  common  adverse  events  reported 
were diarrhea (70%), rash (20%), fatigue (19%), and 
nausea (19%).33
A second phase II study enrolled 19 patients with 
comparable eligibility criteria and the same primary 
endpoint  (RECIST  response  criteria).    However, 
a lower dose (100 mg) was used in this study, with 
escalation  possibility  to  300  mg  upon  disease 
  progression. Objective partial responses were seen in 
16% of patients, and stable disease in 53% of patients. 
Consequently, disease control was seen in 68% of all 
patients. The adverse effects were similar to the pre-
vious studies.34
Phase III studies: randomized placebo-
controlled trial
The promising results observed in phase II   studies 
encouraged  a  large  double-blind,  randomized, 
phase III study. A total of 331 patients were enrolled 
between December 2006 and November 2007 and 
randomly assigned to receive 300 mg of Vandetanib 
or placebo (2:1 ratio). The eligibility criteria included 
metastatic or locally advanced unresectable disease, 
a performance status between 0 and 2 according to 
World Health Organization (WHO) classification, and 
serum calcitonin levels $500 pg/mL. Exclusion cri-
teria were other severe medical conditions or recent 
chemotherapy or radiation-therapy (less than 4 weeks 
before randomization). The data cutoff occurred in 
July 2009 (median follow-up 24 months). The pri-
mary endpoint was progression-free survival (PFS) 
determined by the RECIST criteria. In this cohort, 
a large majority of patients had sporadic (90%) and 
metastatic (95%) MTC. 59% of the patients receiv-
ing   Vandetanib had a confirmed RET mutation, and 
40% had an unknown RET status. The primary end-
point was met: at 6 months, 83% of the patients on 
  Vandetanib  had  progression-free  survival  versus 
63% in the   placebo group. The median progression-
free survival was 19.3 in the placebo group and had 
not been reached at data cut-off in the Vandetanib 
group. Weibull models indicate a predicted median 
  progression-free survival of 30.5 months on   treatment. 
In the Vandetanib group, the secondary efficacy end-
points showed an objective response rate in 45% of 
patients, a disease control rate in 87% of patients, 
and calcitonin and CEA biochemical response rates 
of 69% and 52% of patients, respectively. The over-
all survival was immature at data cutoff. However, 
there was no significant survival difference between 
the two groups during the early follow-up. More pre-
cise data on survival will be available once 50% of 
the patients have died. The adverse events were simi-
lar to those observed in the phase II studies. However, 
5 patients on Vandetanib had adverse events leading 
to death, including arrhythmia and acute heart fail-
ure.35    Vandetanib  was  approved  by  the  Food  and 
Drug Administration  (FDA)  on April  6,  2011  and 
became the first systemic agent to be approved for 
locally advanced or metastatic MTC in the United 
States.36 It is commercialized by AstraZeneca under 
the  Caprelsa®  brand  name  in  the  United  States. 
  Figure 2 summarizes and compares the main results 
of the phase II and III studies.
Safety and tolerability of vandetanib
The clinical studies leading to Vandetanib approval 
showed an acceptable safety and tolerability profile 
with  a  majority  of  the  adverse  events  manageable 
with supportive therapy or dose reduction. However 
adverse  events  such  as  rash,  diarrhea  and  nausea 
were commonly observed even at the lowest dosage. 
The Table 1 summarizes the most common adverse 
events  observed  in  the  clinical  studies  leading  to 
Vandetanib approval. The phase III study uncovered 
potentially life threatening adverse events. Protocol 
defined  QTc  prolongation  was  observed  in  8%  of 
the patients on treatment but no torsades de pointes 
were reported. Five out of the 231 patients on Van-Degrauwe et al
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Table 1. Summary of adverse events observed in the main clinical studies leading to vandetanib approval.
phase I,  
Holden et al 
50–600 mg
phase I,  
Tamura et al 
100–400 mg
phase II,  
Wells et al 
300 mg
phase III,  
Wells et al 
300 mg
phase III,  
Wells et al 
placebo
Diarrhea (%) 38 61 70 56 26
Rash (%) 34 72 67 45 11
Nausea (%) 19 22 63 33 16
Hypertension (%) 18 39 33 32 5
Fatigue (%) 18 44 63 24 23
eCG QTc prolongation (%) 9 67 20 14 1
Adverse events leading  
to death (n)
0 0 0 5 0
Overview of the phase II and III studies
# = Not reported
* = Estimation
Phase II Vandetanib 300 mg/d (Wells et al)
Phase III Vandetanib 300 mg/d (Wells et al)
Phase III placebo (Wells et al)
Phase II Vandetanib initially 100 mg/d
(Robinson et al)
20 53
53 68
87
71
73 27.9
30.5*
19.3
#
43
58
Partial responders 
or better (%)
Durable stable
disease (%) Disease control (%)
16
45
13
Median progression
free survival
(months)
100
90
80
70
60
50
40
30
20
10
0
Figure 2. Analysis of clinical trials leading to the approval of vandetanib.
detanib   experienced adverse events leading to death 
including  aspiration  pneumonia,  respiratory  arrest, 
respiratory failure, staphylococcal sepsis, arrhythmia 
and acute cardiac failure. Recently, a meta-analysis of 
9 phase II or phase III studies evaluated the incidence 
of QTc prolongation in 2188 cancer patients treated 
with 300 mg Vandetanib a day. The overall incidence 
of all grade and high-grade QTc prolongation was 
respectively,  18%  and  12%  among  thyroid  cancer 
patients. The incidence was significantly higher in 
patients treated for thyroid cancer compared to other 
solid tumors, probably because of the longer treat-
ment duration or as a result of abnormal thyroid func-
tion which can increase the susceptibly to acquire 
prolonged  QTc  intervals.37  Another  meta-analysis 
  evaluated the rash incidence in 2961 patients treated 
with 300 mg   Vandetanib a day and found that the over-
all incidence of all-grade and high-grade rash were 
46.1% and 3.5%, respectively.38 Other rare adverse 
events  related  to  Vandetanib  have  been  described 
in the literature such as Stevens-Johnson syndrome 
or  ischemic  cerebrovascular  events.39,40  Due  to  the 
frequent  and  potentially  life  threatening  adverse 
events a strategy called Vandetanib Risk Evaluation 
  Mitigation Strategy (REMS) which allows prescrip-
tion and distribution of the drug only by physicians 
and pharmacies certified by the REMS program, has 
been  developed.41  Indeed,  to  prescribe  Caprelsa® 
physicians  need  to  complete  a  prescriber  training, 
review the Caprelsa® education pamphlet and the full vandetanib for medullary thyroid cancer
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  prescribing information and to be re-trained   following 
substantive  changes  in  the  Caprelsa®  REMS.  The 
Caprelsa®  enrollment  form  emphasizes  that  elec-
trolytes should be closely monitored while on treat-
ment, that drugs prolonging the QT interval should be 
avoided and that ECGs must be obtained   periodically. 
If patients develop a QTc greater than 500 ms the 
treatment  should  be  discontinued  until  the  QTc 
returns to less than 450 ms and subsequently resumed 
at a lower dose. For additional safety, Caprelsa® is 
only dispensed by certified pharmacies which meet 
the Caprelsa® REMS requirements such as employee 
education on risks and provide medication guides to 
patients.42
Clinical utility of vandetanib in the 
management of advanced MTC  
and cost considerations
All the previous studies evaluating classic chemo-
therapy regimens or radiation therapy failed to dem-
onstrate  significant  objective  responses  in  patients 
with advanced MTC. Accordingly, the results of the 
phase II and III studies are unique and encouraging. 
The disease can demonstrate an indolent course in 
many patients, some of whom may remain asymp-
tomatic with stable disease for many years. The long-
term survival rates for patients on Vandetanib versus 
placebo will need to be collected, and these will help 
to inform practice guidelines for locally advanced and 
metastatic medullary thyroid cancer going forward. 
The potentially serious cardiac side effects and cost 
of the treatment cannot be overlooked. A study con-
ducted in the Netherlands analyzed the use and costs 
of  oral  anticancer  agents  between  2000  and  2008 
and showed a 50-fold rise in costs of oral anticancer 
agents between 2000 and 2008; 67% of this rise was 
attributable  to  tyrosine  kinase  inhibitors  (TKIs).43 
One of the most effective tyrosine kinase inhibitors, 
imatinib, has been evaluated in many pharmacoeco-
nomic  studies. A  summary  of  6  such  trials,  found 
the medication to be cost effective in the treatment 
of gastro-intestinal stromal tumors (GIST) and also 
noted the cost effectiveness of second line treatment 
with sunitinib in resistant patients.44 MTC however 
is different from GIST as it is a much more indolent 
disease. The 1 year survival of patients with meta-
static GIST, is increased from 32% to 95% with the 
addition of imatinib.44 MTC patients on the contrary 
often are asymptomatic and productive members of 
society. Since 1 month of Vandatinib treatment costs 
approximately $5–10,000, it will be crucial in future 
studies to identify the patients that are the most likely to 
benefit from the treatment as well as the correct time 
to  begin  therapy.  It  is  probable  that  cost  effective 
treatment for metastatic patients will only be seen in 
those who have a life expectancy of a limited number 
of months or years. However, it is also conceivable 
that Vandetanib can be used in a ‘neoadjuvant’ setting 
to convert patients with locally advanced disease to 
an operable status, or that it can be used in tandem 
with other agents under study in order to maximize 
clinical benefit, delaying the need for other support-
ive  services  and  treatments  and  possibly  reducing 
longer term costs. Moreover, a key issue will be to 
evaluate in detail whether Vandetanib contributes to 
enhanced control of pain and improvement of quality 
of life among patients with advanced MTC.
vandetanib in the treatment  
of other malignancies
RET-PTC  rearrangements  are  commonly  found  in 
patients with papillary thyroid cancer and Vandetanib 
has shown activity against this aberrant receptor on 
papillary cancer cell lines.45 Furthermore, differen-
tiated thyroid tumors are highly vascular and might 
consequently respond to anti-angiogenic treatments. 
A phase II study was conducted in patients with locally 
advanced  or  metastatic  differentiated    (papillary  or 
follicular)  thyroid  carcinoma.  This  study  enrolled 
145  subjects  after  radioiodine  failure  or  radioio-
dine  contraindication;  72  received    Vandetanib  and 
73 received placebo. Remarkably, the PFS was sig-
nificantly prolonged in the Vandetanib group versus 
placebo with 11 months and 5.8 months,   respectively. 
However, there was no statistically difference in over-
all survival, disease control rate and overall response 
rate.46
Some  objective  responses  were  seen  in  patients 
with  non-small  cell  lung  carcinoma  (NSCLC)  in 
phase  I  studies.  The  EGFR  pathway  is  commonly 
involved in NSCLC development and EGFR inhibi-
tors  such  as  Erlotinib  and  Gefitinib  are  used  in 
selected patients with NSCLC. It has been proposed 
that resistance to these treatments might be a conse-
quence of increased VEGF expression and signaling.47 
Moreover, it has been shown in xenografts models of Degrauwe et al
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human NSCLC that resistance to EGFR TKIs can be 
reversed by   Vandetanib.48 These results encouraged 
further clinical studies for previously treated NSCLC. 
A phase II study compared   Vandetanib versus Gefitinib 
and showed that Vandetanib significantly prolonged 
PFS.    However,  overall  survival  was  not  signifi-
cantly   different.49 Another phase III study compared 
  Vandetanib with Erlotinib and found no difference in 
PFS but Vandetanib was associated with a higher rate 
of adverse events.50 A recent study evaluated the effec-
tiveness of Vandetanib versus placebo in patients with 
NSCLC after prior treatment with EGFR TKIs. No 
increase in overall survival was found in the   Vandetanib 
group but the PFS and objective response rates were 
slightly  more  favorable  in  the  treated  group.51 The 
effectiveness of Vandetanib in association with Doc-
etaxel52 or Pemetrexed53 has also been assessed in large 
phase III studies. The   Docetaxel-Vandetanib associa-
tion showed a modest prolongation of PFS whereas 
the  Pemetrexed-  Vandetanib  combination  failed  to 
demonstrate  any  prolongation  of  PFS  compared  to 
Pemetrexed alone. Hence, this study showed a delay 
in worsening of lung cancer symptoms and signifi-
cantly higher objective response rates in the patients 
treated with the bi-therapy.
The use of Vandetanib has also been evaluated in 
advanced breast cancer because the EGFR and VEGFR 
pathways play a role in breast cancer growth, progres-
sion and invasion.54 A phase II study evaluated Vande-
tanib 100 mg or 300 mg daily for patients with advanced 
metastatic breast cancer. No objective responses were 
seen, and only 1 patient out of the 46 enrolled had 
stable  disease.55  It  has  been  shown  that Vandetanib 
can induce apoptosis in human breast cancer cell lines 
when used as a single agent or in combination with 
Paclitaxel.56 A phase II study compared the associa-
tion Vandetanib-Docetaxel   versus placebo-Docetaxel 
in pretreated patients with advanced breast cancer but 
the association provided no clinical benefit.57
Several phase I studies for metastatic colorectal cancer 
were recently conducted; in a first study   Vandetanib was 
associated with Capacitabine-  Oxaliplatine and Bevaci-
zumab was added as a fourth agent in one subgroup. The 
association of the two anti-angiogenic drugs resulted in 
severe  diarrhea  requiring  IV  hydration  in  3  out  of  4  patients.58 
Other phase I studies tested the FOLFIRI-Vandetanib59 
or mFOLFOX6-Vandetanib60 associations which were 
generally  well  tolerated.  Larger  studies  will  help  to 
determine  whether  the  addition  of Vandetanib  might 
provide a clinical benefit in colorectal cancer.
Clinical  studies  evaluating  Vandetanib  alone  or 
in combination have also been led in hepatocellular 
carcinoma,61  refractory  prostate  cancer,62  advanced 
urothelial  cancer,63  and  metastatic  pancreatic 
  adenocarcinoma.64 These studies showed globally a 
good tolerance to Vandetanib but failed to demon-
strate any clinical benefit. Further studies are required 
to define whether Vandetanib might play a role in the 
management of these malignancies.
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